Volume 14, Number 7—July 2008
Research
Attributable Outcomes of Endemic Clostridium difficile–associated Disease in Nonsurgical Patients
Table 1
Baseline characteristics of study cohort, Clostridium difficile–associated disease (N = 18,050)*
Characteristic | CDAD case-patients (n = 390), no. (%) | Non–case-patients (n = 17,663), no. (%) | p value† |
---|---|---|---|
Age, y | |||
<45 | 58 (15) | 6,847 (39) | <0.001 |
45–65 | 132 (34) | 5,187 (29) | 0.06 |
>65 |
200 (51) |
5,626 (32) |
<0.001 |
Male sex | 194 (50) | 6,704 (38) | <0.001 |
White race |
257 (66) |
9,860 (56) |
<0.001 |
Modified APS | |||
<2 | 77 (20) | 6,687 (38) | <0.001 |
3–4 | 76 (20) | 4,573 (26) | 0.004 |
5–6 | 82 (21) | 2,970 (17) | 0.028 |
>7 |
155 (40) |
3,430 (19) |
<0.001 |
Liver disease | |||
Mild | 5 (1) | 204 (1) | 0.77 |
Moderate to severe |
6 (2) |
209 (1) |
0.47 |
Diabetes without chronic complications | 70 (18) | 2,718 (15) | 0.17 |
Diabetes with chronic complications |
15 (4) |
416 (2) |
0.06 |
Myocardial infarction | 26 (7) | 1466 (8) | 0.25 |
Congestive heart failure | 97 (25) | 2,562 (15) | <0.001 |
Cerebral vascular disease |
16 (4) |
882 (5) |
0.42 |
Chronic obstructive pulmonary disease | 90 (23) | 2,564 (15) | <0.001 |
Rheumatologic/collagen vascular disease | 11 (3) | 361 (2) | 0.29 |
Peptic ulcer disease | 5 (1) | 279 (2) | 0.64 |
Cancer, excluding leukemia or lymphoma | 45 (12) | 1,283 (7) | 0.001 |
Leukemia or lymphoma | 69 (18) | 567 (3) | <0.001 |
Metastatic solid tumor | 33 (9) | 936 (5) | 0.01 |
HIV/AIDS | 5 (1) | 209 (1) | 0.81 |
Paraplegia or hemiplegia | 8 (2) | 223 (1) | 0.17 |
*CDAD, Clostridium difficile–associated disease; APS, Acute Physiology Score.
† Fisher exact test, χ2 test.